PLATFORM SPECIALTY PRODUCTS CORPORATION

Credit Suisse Basic Materials Conference 2017

September 13, 2017

SAFE HARBOR

PLATFORM SPECIALTY PRODUCTS CORPORATION

Please note that in this presentation, we may discuss events or results that have not yet occurred or been realized, commonly referred to as forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of the Company. Such discussion and statements will often contain words such as “expect,” “anticipate,” “project,” “will,” “should,” “believe,” “intend,” “plan,” “estimate,” “potential,” “target,” and similar expressions, and relate, without limitations, to the Company’s intent to separate its Agricultural Solutions business and create two independent, publicly-traded companies following the proposed separation, the Arysta IPO, the anticipated benefits of the proposed separation, the post-separation balance-sheets of the two companies, as well as the Company’s future vision, including each business’ long-term average growth potential, strategic direction and target leverage following the completion of the proposed IPO and separation. These projections and statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those projected as a result of certain factors, which include, among others, the Company’s ability to successfully separate its Agricultural Solutions business and realize the anticipated benefits from the proposed IPO and separation; the expected timing of filing of a registration statement for the registration of common stock of Arysta in the IPO, the timing for completion of the proposed IPO and separation; adverse effects on the two companies’ business operations or financial results and the market price of the Company’s shares as a result of the completion of the proposed separation; market volatility; legal, tax and regulatory requirements; unanticipated delays and transaction expenses; the impact of the proposed separation on the Company’s employees, customers and suppliers; overall global economic and business conditions impacting the businesses of the two companies; the ability of the two companies to operate independently following the proposed separation; and the possibility of more attractive strategic options arising in the future. Additional information concerning these and other factors that could cause Platform’s actual results to vary is, or will be, included in Platform’s periodic and other reports filed with the Securities and Exchange Commission. Platform undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This presentation also contains unaudited “comparable” financial information which assumes full period contribution of all the Company’s acquired businesses to date: the Chemtura AgroSolutions business of Chemtura Corporation and Percival S.A., or Agriphar, acquired in 2014; Alent plc, Arysta LifeScience Ltd, and the Electronic Chemicals and Photomasks businesses of OM Group, Inc. acquired in 2015; and OMG Electronic Chemicals (M) Sdn Bhd acquired in 2016. This combined information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the Company’s acquisitions been completed as of the dates indicated, or that may be achieved in the future. Historical financial results and information included herein relating to these acquired businesses were derived from public filings, when applicable, and/or information provided by management of these businesses prior to their acquisitions by the Company. Although we believe it is reliable, this information has not been verified, internally or independently. In addition, financial information for some of these acquired businesses was historically prepared in accordance with non-GAAP accounting methods, and may or may not be comparable to the Company’s financial statements. Consequently, there is no assurance that the financial results and information for these legacy businesses included herein are accurate or complete, or representative in any way of the Company’s actual or future results as a consolidated company.

Industry, market and competitive position data described in this presentation were obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. While the Company believes its internal estimates and research are reliable and the market definitions are appropriate, such estimates, research and definitions have not been verified by any independent source. You are cautioned not to place undue reliance on this data.

NON-GAAP INFORMATION

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States ("GAAP"), the Company uses the following non-GAAP financial measures: adjusted EBITDA, adjusted EBITDA margin, cash flow conversion, comparable adjusted EBITDA, comparable adjusted EBITDA margin, return on invested capital (ROIC), and organic sales growth. The Company also evaluates and presents its results of operations on a constant currency basis.

The reconciliations of these non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP can be found in the appendix of this presentation. The Company only provides adjusted EBITDA and organic sales growth expectations and synergy potential on a non-GAAP basis, and does not provide a reconciliation of such forward-looking non-GAAP measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including adjustments that could be made for restructuring, integration and acquisition-related expenses, share-based compensation amounts, adjustments to inventory and other charges reflected in the reconciliation of historic numbers, the amount of which, based on historical experience, could be significant.

Management internally reviews each of these non-GAAP measures to evaluate performance on a comparative period-to-period basis in terms of absolute performance, trends, and expected future performance with respect to the Company's business, and believes that these non-GAAP measures provide investors with an additional perspective on trends and underlying operating results on a period-to-period comparable basis. The Company also believes that investors find this information helpful in understanding the ongoing performance of its operations separate from items that may have a disproportionate positive or negative impact on its financial results in any particular period. These non-GAAP financial measures, however, are not prepared in accordance with GAAP and may not be indicative of the results that the Company expects to recognize for future periods. In addition, these non-GAAP financial measures may differ from measures that other companies may use. These non-GAAP financial measures are therefore supplemental in nature and should not be considered in isolation, or a substitute for, or superior to, the related financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures included herein.

Please see the appendix to this presentation for a more detailed description of each non-GAAP financial measure used by the Company, including the adjustments reflected in each of them and the reason why the Company believes such non-GAAP measures are useful to investors.

PLATFORM SINCE FOUNDING

PLATFORM SPECIALTY PRODUCTS CORPORATION

Platform Thesis

A diversified portfolio of "asset-lite, high-touch" businesses across multiple end-markets can generate stable strong cash flows

Acquisitions & Verticals

Agricultural Solutions	Performance Solutions
Arysta LifeScience, Chemtura AgroSolutions, Agriphar Group	MacDermid, Alent, OMG OM Group
2016 Net Sales: $1.8bn	**2016 Net Sales: $1.8 bn**
2016 Adj. EBITDA*: $401m	**2016 Adj. EBITDA*: $434m**

Key Accomplishments

Agricultural Solutions:

- Integrated three legacy portfolios into one global organization with one sales force & one facility footprint
- Achieved $80m+ of run-rate cost savings within 2 years of Arysta acquisition
- Expanded presence in key geographies building on growth of high-value products like biosolutions and seed treatment
- More than doubled peak potential sales value of new product pipeline to launch through 2025 to ~$1.3bn

Performance Solutions:

- Integrated products, salesforce and R&D organizations to establish five, end-market focused verticals
- Achieved $50m+ of run-rate cost savings within first 18 months
- Realized meaningful growth from combined product portfolio, particularly in Asia
- Developed new capabilities in advanced electronics markets to accelerate growth

* *For definitions of non-GAAP measures, discussions of adjustments and reconciliations, please refer to the appendix of this presentation*

Note: Segment adj. EBITDA excludes corporate cost allocations of $66 million in 2016, with $33 million allocated to each of the Agricultural Solutions and Performance Solutions segments

PLATFORM'S BUSINESS TODAY

PLATFORM SPECIALTY PRODUCTS CORPORATION

✓ **Highly profitable business with minimal capital requirements leading to strong returns on investment …**

2016 Performance

Gross Margin:
42%

Adj. EBITDA* Margin:
21%

Cash Flow Conversion[1]*:
88%

ROIC*:
21%

✓ **Diversified revenue base across geographies and industries…**

2016 Net Sales



2016 Adj. EBITDA: $769m*

✓ **Healthy and growing end-markets with exciting opportunities for expansion…**

Specialty crop protection

Biosolutions

Animal health

Consumer electronics

Automotive

Offshore oil & gas

* *See Non-GAAP footnote on pg. 4*

1. *Cash Flow conversion is calculated as adj. EBITDA less Capex (capital expenditures of $56 million and investments in registrations of products of $36 million) divided by adj. EBITDA*

STRONG FINANCIAL METRICS VS. PEERS

PLATFORM SPECIALTY PRODUCTS CORPORATION

2017E Adj. EBITDA* Growth



2016 Adj. EBITDA* - Capex Margin[1]



2016 ROIC*



2017 EV / Adj. EBITDA*



Note: *R&D Driven Ag peers include Syngenta and Monsanto*
R&D Lite Ag peers include FMC Ag business (ROIC based on FMC), Nufarm, and UPL
Industrial Chemicals peers include Newmarket, Ecolab, Quaker, RPM International, Versum, Cabot Microelectronics, Axalta, and Entegris.
Specialty Chemicals peers include Balchem, Albermarle, Ingevity, W.R. Grace, Valvoline, Hexcel, and H.B. Fuller.

Source: *Public financial filings, Platform management guidance and Wall Street estimates. Platform's Adj. EBITDA growth based mid-point of latest 2017 guidance of $810 million to $830 million. Share prices as of 9/8/2017.*

* *See Non-GAAP footnote on pg. 4*

1. *PAH's Capex incudes capital expenditures of $56 million and investments in registrations of products of $36 million*

PLATFORM'S FUTURE VISION

PLATFORM SPECIALTY PRODUCTS CORPORATION

Two Leading Specialty Chemical Companies with Exciting Growth Opportunities and Robust Cash Flows

	~$1.8bn+[1] Global Agricultural Chemical Business	~$1.8bn+[1] Global Specialty Chemical Business
Key End-Markets	**Conventional crop protection, seed treatment, biosolutions and animal health**	**Electronics, automotive, general industrial, consumer packaging and energy**
Long-Term Average Growth Potential	**~4-5% Organic Sales*** **High single-digit Adj. EBITDA***	**~3-4% Organic Sales*** **High single-digit Adj. EBITDA***
Strategic Direction	■ Develop R&D pipeline and expand strategic partnerships with focus on high value, differentiated solutions for farmers ■ Inorganic opportunities targeting molecule acquisitions, licenses and geographic expansion	■ Leverage global scale and breadth to enter new markets and expand product offerings ■ Measured acquisition approach in existing and adjacent end-markets to enhance long-term value
Target Leverage	**~3.5x Net Debt / Adj. EBITDA*** **Within ~12 months from separation**	**4.0 – 4.5x Net Debt / Adj. EBITDA*** **Within 12 - 18 months from separation**

* *See Non-GAAP footnote on pg. 4*

1. *Based on 2016 net sales*

ARYSTA LIFESCIENCE HIGHLIGHTS

Strong Industry Positioning

- Distinctive position as formulation-based Ag chemical company with global scale and niche crop focus
- Industry innovator that develops new solutions for farmers
- A preferred partner for numerous discovery-focused firms
- Significant global presence in fast growing biosolutions with top-tier position in bio-stimulants[1]

Significant Headroom for Growth

- Organic investments targeting high-growth, highly-differentiated market segments
- Rapid expansion of biosolutions portfolio
- Develop direct sales presence in targeted expansion markets
- Inorganic opportunities targeting molecule acquisitions, licenses and geographic expansion

Robust Product Portfolio & Pipeline

- Diverse product base across herbicides, fungicides, insecticides and biosolutions
- ~$1.3 billion of peak potential sales value for products to launch through 2025

Attractive Financial Profile[2]

2016:

- Organic sales* growth of 3%
- 22% adj. EBITDA* margin
- 85% cash flow conversion[3*]



* See Non-GAAP footnote on pg. 4
1. Based on 2015 sales
2. Segment Adj. EBITDA excludes corporate cost allocations
3. Cash Flow conversion is calculated as adj. EBITDA less Capex (capital expenditures of $24 million and investments in registrations of products of $36 million) divided by adj. EBITDA

ARYSTA LIFESCIENCE PEER BENCHMARKING

2017E Adj. EBITDA* Growth



2016 ROIC*



Note: *R&D Driven Ag peers include Syngenta and Monsanto*
R&D Lite Ag peers include FMC Ag business (ROIC based on FMC), Nufarm, and UPL
Source: *Public financial filings and Wall Street estimates*
* *See Non-GAAP footnote on pg. 4*

PERFORMANCE SOLUTIONS HIGHLIGHTS

Leading Market Positions

- Market leader in specialty chemicals for surface treatment and electronic assembly
- High-touch sales force embedded with customers
- Leading specialty chemical supplier selling more than $1.5 billion of surface chemistry and assembly solutions across electronic and industrial end-markets

Focused Growth Strategy

- Focus on fast growing markets including semiconductor and automotive
- Increasing specification-based business
- Ample opportunity remaining in existing and adjacent end-markets for inorganic growth

Remaining Revenue and Cost Synergies

- Significant opportunity to continue to leverage broadest industry offering with large customers in supply chain of global OEMs
- Estimated ~$20 million savings remaining primarily in facilities and procurement

Attractive Financial Profile[1]

2016:

- Organic sales* growth of 1%; 1H 2017 organic sales* growth of 5%
- 25% adj. EBITDA* margin
- 93% cash flow conversion[2*]



* See Non-GAAP footnotes on pg. 4
1. Segment Adj. EBITDA excludes corporate cost allocations
2. Cash Flow conversion is calculated as adj. EBITDA less Capex (capital expenditures of $32 million) divided by adj. EBITDA

PERFORMANCE SOLUTIONS PEER BENCHMARKING

PLATFORM SPECIALTY PRODUCTS CORPORATION

2017E Adj. EBITDA* Growth



2016 ROIC*



Note: *Industrial Chemicals peers include Newmarket, Ecolab, Quaker, RPM International, Versum, Cabot Microelectronics, Axalta, and Entegris*
Specialty Chemicals peers include Balchem, Albermarle, Ingevity, W.R. Grace, Valvoline, Hexcel, and H.B. Fuller
Source: *Public financial filings and Wall Street estimates*
* *See Non-GAAP footnote on pg. 4*

NEXT STEPS AND OTHER CONSIDERATIONS

- **Arysta IPO :** Expect IPO to be completed mid-2018
  - Arysta to be operated as an independent, standalone public company post-IPO with Platform continuing as a significant shareholder

- **Team:** Strong management teams to be established for both businesses; expect key leaders to be communicated prior to filing final S-1
  - Separation expected to be neutral to Platform from a corporate cost standpoint
    - Expect combined post-separation corporate expense to be flat to down compared to 2017 consolidated expense

- **Tax:** It is expected the IPO of Arysta will not result in the payment of any taxes by Platform or its shareholders

2017 PRIORITIES

PLATFORM SPECIALTY PRODUCTS CORPORATION

Execution: Build on Operating Momentum

Focus Commercial Efforts on Fast Growing Niches

Synergy Realization and Continuous Cost Improvement

Generate Free Cash Flow and Reduce Leverage

APPENDIX

PLATFORM RECONCILIATION TO ADJUSTED EBITDA

PLATFORM SPECIALTY PRODUCTS CORPORATION

(Amounts in millions)	Q2'17 YTD	Q2'16 YTD	FY 2016	FY 2015	FY 2014
Net loss attributable to common stockholders	**$(86)**	**$(144)**	**$(41)**	**$(309)**	**$(263)**
Gain on amendment of Series B Convertible Preferred Stock	—	—	(33)	—	—
Stock dividend on founder preferred shares	—	—	—	—	233
Net income (loss) attributable to the non-controlling interests	2	1	(3)	4	6
Income tax expense (benefit)	30	45	29	75	(7)
Loss before income taxes and non-controlling interests	**(54)**	**(97)**	**(48)**	**(229)**	**(31)**
Adjustments to reconcile to Adjusted EBITDA:					
Interest expense, net	174	191	376	214	38
Depreciation expense	37	37	75	49	21
Amortization expense	136	131	267	202	67
Restructuring expense	12	12	31	25	3
Amortization of inventory step-up	—	12	12	77	36
Acquisition and integration costs	4	24	33	122	48
Non-cash change in fair value contingent consideration	2	4	5	7	29
Legal settlements	(11)	(3)	(3)	(16)	—
Foreign exchange loss on foreign denominated external and internal long-term debt	69	47	34	46	1
Fair value loss on foreign exchange forward contract	—	—	—	74	—
Goodwill impairment	—	—	47	—	—
Gain on settlement agreement related to Series B Convertible Preferred Stock	—	—	(103)	—	—
Non-cash change in fair value of preferred stock redemption liability	—	—	5	—	—
Debt refinancing costs	14	—	20	—	—
Other expense (income), net	15	3	19	(3)	1
Adjusted EBITDA	**$398**	**$361**	**$769**	**$568**	**$212**

Note: Totals may not sum due to rounding

SEGMENT ADJUSTED EBITDA RECONCILIATION

(amounts in millions)	Performance Solutions			Agricultural Solutions			Total		
	Q2'17 YTD	Q2'16 YTD	YoY%	Q2'17 YTD	Q2'16 YTD	YoY%	Q2'17 YTD	Q2'16 YTD	YoY%
Adj. EBITDA ex-corp cost	$220	$197	11%	$209	$197	6%	$429	$395	9%
Corporate allocations	(15)	(17)		(15)	(17)		(30)	(33)	
Comparable Adj. EBITDA	**205**	**181**	**13%**	**193**	**181**	**7%**	**398**	**361**	**10%**
Adj. EBITDA ex-corp cost	220	197	11%	209	197	6%	429	395	9%
Foreign exchange translation	6			3			8		
Comparable Constant Currency ex-corp cost	$226	$197	14%	$211	$197	7%	$437	$395	11%

(amounts in millions)	Performance Solutions			Agricultural Solutions			Total		
	2016	2015	YoY%	2016	2015	YoY%	2016	2015	YoY%
Adj. EBITDA ex-corp cost	$434	$236	84%	$401	$379	6%	$835	$616	36%
Acquisitions:									
Alent		143						143	
OM		28						28	
Arysta					3			3	
Comparable Adj. EBITDA ex-corp cost	434	407	7%	401	382	5%	835	790	6%
Corporate allocations	(33)	(24)		(33)	(24)		(66)	(48)	
Comparable Adj. EBITDA	401	384	5%	368	358	3%	769	742	4%
Foreign exchange translation	15			0			16		
Comparable Constant Currency	417	384	9%	369	358	3%	785	742	6%
Comparable Constant Currency ex-corp cost	$450	$407	10%	$401	$382	5%	$851	$790	8%

Note: Totals may not sum due to rounding

SEGMENT ADJUSTED EBITDA RECONCILIATION (CONTINUED)

PLATFORM SPECIALTY PRODUCTS CORPORATION

(amounts in millions)	Performance Solutions			Agricultural Solutions			Total		
	2015	2014	YoY%	2015	2014	YoY%	2015	2014	YoY%
Adj. EBITDA ex-corp cost	**$236**	**$212**	**11%**	**$379**	**$16**	**n/m**	**$616**	**$228**	**170%**
Acquisitions:									
Alent	143	175					143	175	
OM	28	30					28	30	
Arysta				3	293		3	293	
CAS					90			90	
Agriphar					48			48	
Comparable Adj. EBITDA ex-corp cost	**407**	**417**	**(2)%**	**382**	**447**	**(14)%**	**790**	**863**	**(9)%**
Corporate allocations	(24)	(8)		(24)	(8)		(48)	(16)	
Comparable Adj. EBITDA	**384**	**408**	**(6)%**	**358**	**439**	**(18)%**	**742**	**847**	**(12)%**
Foreign exchange translation		(25)		6	(70)		6	(95)	
Comparable Constant Currency	**384**	**383**	**0%**	**364**	**369**	**(1)%**	**748**	**752**	**(1)%**
Comparable Constant Currency ex-corp cost	**$407**	**$392**	**4%**	**$388**	**$377**	**3%**	**$796**	**$768**	**4%**

Note: Totals may not sum due to rounding. 2015 constant currency calculation used full year 2015 average exchange rates per historical methodology.

SEGMENT COMPARABLE SALES RECONCILIATION

(amounts in millions)	Performance Solutions		Agricultural Solutions		Total	
	2015	2014	2015	2014	2015	2014
Net Sales	**$801**	**$755**	**$1,742**	**$88**	**$2,542**	**$843**
<u>Acquisitions:</u>						
Alent	847	1,063			847	1,063
OM	142	172			142	172
Arysta			87	1,533	87	1,533
CAS				380		380
Agriphar				170		170
Comparable Sales	**$1,791**	**$1,990**	**$1,829**	**$2,171**	**$3,620**	**$4,161**

Note: Totals may not sum due to rounding

SEGMENT ORGANIC SALES GROWTH RECONCILIATION

PLATFORM SPECIALTY PRODUCTS CORPORATION

	Q2'17 YTD					
	Reported Net Sales Growth	Impact of Currency	Constant Currency	Metals	Acquisitions	Organic Sales Growth
Performance Solutions	6%	2%	8%	(3)%	—%	**5%**
Agricultural Solutions	1%	(1)%	—%	—%	—%	**—%**
Platform	**3%**	**1%**	**4%**	**(1)%**	**—%**	**3%**

	FY 2016					
	Reported Net Sales Growth	Impact of Currency	Constant Currency	Metals	Acquisitions	Organic Sales Growth
Performance Solutions	121%	3%	2%	(1)%	123%	**1%**
Agricultural Solutions	4%	2%	1%	0%	3%	**3%**
Platform	**41%**	**2%**	**1%**	**0%**	**41%**	**2%**

Note: Totals may not sum due to rounding

RETURN ON INVESTED CAPITAL RECONCILIATION

($ in millions)	Performance Solutions 2016	Agricultural Solutions 2016	Total 2016
Adj. EBITDA	**$401**	**$368**	**$769**
(+) Rent expense	22	15	37
(+) R&D expense	45	39	84
(-) Statutory tax rate impact	(164)	(147)	(312)
Adj. Operating Income	**$304**	**$275**	**$579**
Invested Capital			
Total Assets	**$4,466**	**$5,588**	**$10,054**
(-) current liabilities excluding current installments of long-term debt and revolving credit facilities	(323)	(643)	(967)
(+) Accumulated depreciation	70	51	120
(+) Capitalized rent expense	174	119	294
(+) Capitalized R&D[1] expense	225	379	604
(-) Goodwill & net intangible assets	(3,341)	(4,071)	**(7,412)**
Invested Capital	**$1,271**	**$1,423**	**$2,693**
Return on Invested Capital (ROIC)	**24%**	**19%**	**21%**

Note: Totals may not sum due to rounding

1. *For purposes of capitalizing R&D in the Agricultural Solutions business, $36 million of 2016 investments in product registrations has also been included to accurately capture the total R&D spent in the business*

NON-GAAP INFORMATION

Adjusted EBITDA:

Adjusted EBITDA is defined as earnings before interest, taxes, depreciation and amortization, as further adjusted for additional items included in earnings that are not representative or indicative of our ongoing business. Management believes adjusted EBITDA and adjusted EBITDA margin provide investors with a more complete understanding of the long-term profitability trends of Platform's business, and facilitate comparisons of its profitability to prior and future periods.

Cash Flow Conversion:

Free Cash Flow conversion is calculated as Adj. EBITDA less Capex (capital expenditures and investments in registrations of products) divided by adj. EBITDA. Management believes this is an important measure in evaluating the Company's financial performance and measuring the Company's ability to generate cash without incurring additional external financings or significant re-investments.

Comparable Adjusted EBITDA:

Comparable adjusted EBITDA is defined as Adjusted EBITDA adjusted to reflect acquisitions and the related financings as though they had occurred on January 1, 2015 without the impact of purchase accounting. Adjusted EBITDA and comparable adjusted EBITDA are key metrics used by management to measure operating performance and trends. In particular, the exclusion of certain expenses in calculating adjusted EBITDA and comparable adjusted EBITDA facilitates operating performance comparisons on a period-to-period basis. Management believes comparable Adjusted EBITDA provides investors with a more complete understanding of the long-term profitability trends of Platform's business, and facilitates comparisons of its profitability to prior and future periods.

Comparable Constant Currency ("Comparable CC"):

Constant currency presentation excludes the impact of fluctuations in foreign currency exchange rates. Constant currency percentages are calculated by converting the current-period local currency financial results into U.S. Dollar using the prior period's exchange rates and comparing these adjusted amounts to our prior period reported results. The difference between actual growth rates and constant currency growth rates represents the impact of foreign currency. The comparable constant currency presentation includes actual results adjusted to reflect acquisitions and related financings as though they had occurred at the beginning of the previous period adjusted for the effects of purchase accounting on actual results. Management believes that this presentation provides a more complete understanding of the Company's operational results and a meaningful comparison of its performance between periods. However, this comparable financial information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the Company's acquisitions been completed as of the dates indicated, or that may be achieved in the future.

Organic Sales Growth:

Organic sales growth is defined as net sales excluding the impact of foreign currency translation, changes due to the price of certain metals, and acquisitions and/ or divestitures, as applicable. Management believes this non-GAAP financial measure provides investors with a more complete understanding of the underlying net sales trends by providing comparable sales over differing periods on a consistent basis.

For the three and six months ended June 30, 2017, metals pricing had a positive impact on Performance Solutions' results of $8.9 million and $21.9 million, respectively. For the six months ended June 30, 2016, Performance Solutions' results benefitted from acquisitions by $2.8 million.

Return on Invested Capital (ROIC):

Return on Invested Capital (ROIC) is defined as {net operating profit plus rent expense, R&D, amortization and depreciation less statutory tax impacts} / invested capital. Invested capital is defined as total assets plus 8x annual rent expense plus 5x annual R&D plus accumulated depreciation less non-interest bearing current liabilities less goodwill & net intangible assets. Assumes statutory tax rate. For Platform, Adj. EBITDA was used as a proxy for net operating profit plus amortization and depreciation. Management believes ROIC is an important measure for evaluating the long-term efficiency and productivity of the Company's capital investments.